It had already showed that several
thromboxane A(2)
receptor (TP receptor) antagonists might be utilized in the treatment of
cardiovascular diseases. In addition, recent reports suggested that
TP receptor antagonism may be able to restrict vascular
inflammation in atherosclerotic vessels. In particular,
S18886 has been developed as a non-
prostanoid TP receptor antagonist derived from
sulotroban that is characterized by a tetrahydronaphthalene ring as a spacer between the 4-cholophenylsulfonamide group and
carboxylic acid. Several reports using experimental animal models of
atherosclerosis indicated that
S18886 caused a regression of advanced
atherosclerosis. More recently, several studies and patents showed that new
thromboxane modulators combined with another pharmacological activities have been developed. Ohtake et al. discovered
TRA-418 (a
benzene-condensed heterocyclic derivative) having a
TP receptor antagonistic activity and a
prostaglandin I(2) receptor agonistic activity. Cesagrande found that 4-methyl-N- (4-trans-nitrooxycyclohexyl)-N-(3-pyridinylmethyl)-1,3- benzenedicarboxamide is endowed with anti-
thromboxane and NO-donor actions. Oketani et al. discovered that
E3040, a novel
benzothiazole derivative, inhibited TXA(2) synthase and 5-LO activities. EK112, a combined
angiotensin II and
TP receptor antagonist, was developed. These new compounds may be able to restrict further infiltration of inflammatory cells in atherosclerotic vessels, thus stabilizing vulnerable plaques in the related
cardiovascular diseases.